TWI738774B - 眼用組成物 - Google Patents

眼用組成物 Download PDF

Info

Publication number
TWI738774B
TWI738774B TW106114962A TW106114962A TWI738774B TW I738774 B TWI738774 B TW I738774B TW 106114962 A TW106114962 A TW 106114962A TW 106114962 A TW106114962 A TW 106114962A TW I738774 B TWI738774 B TW I738774B
Authority
TW
Taiwan
Prior art keywords
ophthalmic composition
patent application
scope
item
chlorhexidine
Prior art date
Application number
TW106114962A
Other languages
English (en)
Chinese (zh)
Other versions
TW201740928A (zh
Inventor
優瑞 史哈特
Original Assignee
美商沙希公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商沙希公司 filed Critical 美商沙希公司
Publication of TW201740928A publication Critical patent/TW201740928A/zh
Application granted granted Critical
Publication of TWI738774B publication Critical patent/TWI738774B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106114962A 2016-05-06 2017-05-05 眼用組成物 TWI738774B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662332789P 2016-05-06 2016-05-06
US62/332,789 2016-05-06
US201662337571P 2016-05-17 2016-05-17
US62/337,571 2016-05-17

Publications (2)

Publication Number Publication Date
TW201740928A TW201740928A (zh) 2017-12-01
TWI738774B true TWI738774B (zh) 2021-09-11

Family

ID=58709627

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106114962A TWI738774B (zh) 2016-05-06 2017-05-05 眼用組成物

Country Status (10)

Country Link
US (2) US10610499B2 (enExample)
EP (1) EP3452093B1 (enExample)
JP (1) JP6941157B2 (enExample)
CN (1) CN109715215A (enExample)
AU (1) AU2017261303B9 (enExample)
BR (1) BR122024001664A2 (enExample)
CA (1) CA3022983C (enExample)
DK (1) DK3452093T3 (enExample)
TW (1) TWI738774B (enExample)
WO (1) WO2017192944A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610499B2 (en) 2016-05-06 2020-04-07 SaCSh Corp. Ophthalmic compositions
KR102340804B1 (ko) * 2019-07-22 2021-12-17 주식회사 휴온스메디케어 클로르헥시딘 또는 이의 유도체를 포함하는 항균 지속성이 개선된 수용성 소독용 조성물 및 이를 포함하는 섬유형 소독제
US20220409633A1 (en) * 2019-12-03 2022-12-29 Ntc S.R.L. Composition comprising budesonide for ophthalmic use
US12357594B1 (en) 2021-06-30 2025-07-15 Sage Products, Llc Antimicrobial solution for pre-operative preparation
US11951087B2 (en) * 2021-07-27 2024-04-09 Lanny Leo Johnson Eye wash compositions and methods
WO2025176750A1 (en) 2024-02-23 2025-08-28 Heinrich-Heine-Universität Düsseldorf Dual targeting in a new class of active ingredients
CN119792261B (zh) * 2025-03-14 2025-07-11 华中科技大学同济医学院附属同济医院 治疗泌尿系感染的抗菌剂及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO59572A2 (enExample) 1972-01-29 1976-03-15
JP3781792B2 (ja) * 1993-12-27 2006-05-31 千寿製薬株式会社 ジフルプレドナート含有点眼用懸濁液剤
AU684115B2 (en) * 1993-12-27 1997-12-04 Mitsubishi Chemical Corporation Ophthalmic suspension containing diflupredonate
ATE215821T1 (de) * 1995-01-20 2002-04-15 Wakamoto Pharma Co Ltd Entzündungshemmende augentropfen
GB9616208D0 (en) * 1996-08-01 1996-09-11 Smithkline Beecham Plc Novel Compounds
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
US6872705B2 (en) 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
DE102005046769A1 (de) * 2005-09-29 2007-04-05 Berlin-Chemie Ag Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus)
WO2009006130A2 (en) 2007-06-28 2009-01-08 Bausch & Lomb Incorporated Salt free hyaluronate ophthalmic solution
JP2012520880A (ja) * 2009-03-17 2012-09-10 アーシエックス セラピューティックス， インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
CN102973925A (zh) * 2012-11-27 2013-03-20 顾月燕 一种促进伤口愈合的组合物的制备方法
CA2933065C (en) * 2013-12-12 2021-08-24 Innovation Technologies, Inc. Materials and methods for controlling infections
US10610499B2 (en) 2016-05-06 2020-04-07 SaCSh Corp. Ophthalmic compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chlorhexidine Monotherapy with Adjunctive Topical Corticosteroids for Acanthamoeba Keratitis, Journal Ophthalmic Vis Res 2015; 10 (2): 106-111
Chlorhexidine Monotherapy with Adjunctive Topical Corticosteroids for Acanthamoeba Keratitis, Journal Ophthalmic Vis Res 2015; 10 (2): 106-111 Goshe et al., Cleveland Clinic Ophthalmology Update Spring 2012 pp. 1-12 published 2012 *
Goshe et al., Cleveland Clinic Ophthalmology Update Spring 2012 pp. 1-12 published 2012

Also Published As

Publication number Publication date
CA3022983A1 (en) 2017-11-09
AU2017261303A1 (en) 2018-11-22
BR112018072647A2 (pt) 2019-02-19
JP6941157B2 (ja) 2021-09-29
US10610499B2 (en) 2020-04-07
WO2017192944A1 (en) 2017-11-09
CN109715215A (zh) 2019-05-03
EP3452093B1 (en) 2021-04-28
US20170319515A1 (en) 2017-11-09
CA3022983C (en) 2024-05-07
BR122024001664A2 (pt) 2024-02-27
AU2017261303B9 (en) 2021-09-23
US10632083B2 (en) 2020-04-28
JP2019515040A (ja) 2019-06-06
EP3452093A1 (en) 2019-03-13
US20180147162A1 (en) 2018-05-31
DK3452093T3 (da) 2021-06-28
AU2017261303B2 (en) 2021-09-16
TW201740928A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
US10632083B2 (en) Ophthalmic compositions
CN103463635B (zh) 包含聚维酮碘的眼用组合物
BRPI0710615A2 (pt) métodos e composições para o tratamento de infecção ou colonização infecciosa da pálpebra, da superfìcie ocular, da pele ou da orelha
CN103945853A (zh) 眼用制剂
TW202014194A (zh) 抗微生物功效增強且毒性降低之亞氯酸鈉組成物
JPWO2018203424A1 (ja) 点眼剤
US20100323978A1 (en) Non-aqueous oil delivery system for ophthalmic drugs
BR112018072647B1 (pt) Composições oftálmicas
US20210290527A1 (en) Compositions and Methods for Treatment of Ocular Conditions
HK1192720B (en) Ophthalmic compositions comprising providone-iodine
HK1192720A (zh) 包含聚维酮碘的眼用组合物
HK1130665A (en) Ophthalmic compositions comprising povidone-iodine
HK1130665B (en) Ophthalmic compositions comprising povidone-iodine